Annals of OncologyPub Date : 2026-10-26DOI: 10.1016/j.annonc.2026.10.1284
L Xie, W Yao, Y Hua, W Luo, C Tu, J Wang, J Chen, B Li, D Zhu, X Li, Y Xiao, J Ma, H Hu, M Fang, Z Huang, H Wang, Q Liu, Y Jin, X Zhang, X Niu, X Tang
{"title":"Efficacy and safety of risvutatug rezetecan versus gemcitabine-docetaxel in relapsed or refractory osteosarcoma: primary results from the ARTEMIS-011 phase III trial.","authors":"L Xie, W Yao, Y Hua, W Luo, C Tu, J Wang, J Chen, B Li, D Zhu, X Li, Y Xiao, J Ma, H Hu, M Fang, Z Huang, H Wang, Q Liu, Y Jin, X Zhang, X Niu, X Tang","doi":"10.1016/j.annonc.2026.10.1284","DOIUrl":"10.1016/j.annonc.2026.10.1284","url":null,"abstract":"<p><strong>Background: </strong>Patients with relapsed or refractory (R/R) osteosarcoma have a poor prognosis and high unmet needs for effective therapies. In this article, we report primary results from ARTEMIS-011, the multicenter, open-label, randomized phase III trial of risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, in Chinese patients with R/R osteosarcoma after 2 or more prior lines of systemic treatment.</p><p><strong>Patients and methods: </strong>Patients (aged ≥12 years) were randomly assigned 2 : 1 to Ris-Rez 12.0 mg/kg or gemcitabine-docetaxel (GD), administered every 3 weeks, stratified by age and lung metastasis. The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR); secondary endpoints included overall survival (OS) and safety.</p><p><strong>Results: </strong>At data cut-off (17 June 2026), 80 patients were treated with Ris-Rez and 42 with GD; median follow-up was 7.1 months. Median age was 21 years (interquartile range 17-34) with 31 (25%) adolescents (12 to <18 years). BICR-assessed PFS significantly improved with Ris-Rez compared with GD [median 5.5 compared with 1.4 months; hazard ratio (HR) 0.33, 95% confidence interval (CI) 0.20-0.55, P < 0.0001]. OS data were immature, with an HR of 0.51 (95% CI 0.21-1.23). With longer treatment duration with Ris-Rez than GD (median 4.5 compared with 1.5 months), adverse events (AEs) were reported in all patients. No treatment-related AEs (TRAEs) led to death. Grade ≥3 TRAEs occurred in 93% of patients with Ris-Rez and 83% with GD, and serious TRAEs in 64% compared with 29%, which were predominantly hematologic. TRAEs led to dose reductions in 71% of patients with Ris-Rez compared with 26% of patients with GD, and permanent discontinuation was infrequent (3.8% compared with 2.4%).</p><p><strong>Conclusions: </strong>In ARTEMIS-011, Ris-Rez demonstrated a statistically significant and clinically meaningful improvement in BICR-assessed PFS compared with GD, alongside a numerical trend toward improved OS and a manageable safety profile with dose modifications and supportive care, offering a promising new treatment option for patients with R/R osteosarcoma.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2026-10-25DOI: 10.1016/j.annonc.2026.10.104
J Bennouna, T André, E Martin, C Cremolini, S Gill, T Asmis, P Kavan, E Mitry, S Hiret, L Mineur, P Artru, C Perret, O Bouché, Y Touchefeu, B Goldenberg, O Dupuis, S Lonardi, B Chibaudel, H Castanié, C Coutzac, L Bauguion, E Guardiola, A Benmaziane, J Barrière, E Chen, V Simmet, G Allegrini, F Marmorino, V Pezzella, L Monard, L Campion, C O'Callaghan, J Taieb
{"title":"A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: results of the international IROCAS study.","authors":"J Bennouna, T André, E Martin, C Cremolini, S Gill, T Asmis, P Kavan, E Mitry, S Hiret, L Mineur, P Artru, C Perret, O Bouché, Y Touchefeu, B Goldenberg, O Dupuis, S Lonardi, B Chibaudel, H Castanié, C Coutzac, L Bauguion, E Guardiola, A Benmaziane, J Barrière, E Chen, V Simmet, G Allegrini, F Marmorino, V Pezzella, L Monard, L Campion, C O'Callaghan, J Taieb","doi":"10.1016/j.annonc.2026.10.104","DOIUrl":"10.1016/j.annonc.2026.10.104","url":null,"abstract":"<p><strong>Background: </strong>Patients with pT4 and/or pN2 stage III colon cancer remain at high risk of recurrence despite oxaliplatin-based adjuvant chemotherapy. We evaluated whether intensification with modified FOLFIRINOX improved outcomes compared with modified FOLFOX6.</p><p><strong>Patients and methods: </strong>In this international, academic, open-label, randomised phase III trial conducted by Partenariat de Recherche en Oncologie DIGEstive (PRODIGE) in France, Canadian Cancer Trials Group in Canada, and Gruppo Oncologico del Nord Ovest in Italy, patients with stage III colon adenocarcinoma after R0 resection presenting T4 and/or N2 were randomly assigned (1 : 1) to receive mFOLFIRINOX or mFOLFOX6 every 2 weeks for 12 cycles. The primary endpoint was 3-year disease-free survival (DFS) in the intention-to-treat population.</p><p><strong>Results: </strong>Between May 2017 and June 2023, 795 patients were assigned to mFOLFIRINOX (n = 398) or mFOLFOX6 (n = 397). Median age was 59 years (range 19-75); 39.7% were women, 52.8% had pT4 disease, 72.2% had pN2 disease, and 25.3% had both. At a median follow-up of 55 months (interquartile range 42.6-65.9), 284 DFS events had occurred: 146 with mFOLFIRINOX and 138 with mFOLFOX6. Three-year DFS was 65.6% versus 66.3%, respectively [hazard ratio (HR) 1.07, 95% confidence interval (CI) 0.84-1.36; P = 0.61). Although overall survival (OS) data remain immature, 3-year OS was 91.2% versus 86.7% (HR 0.85, 95% CI 0.61-1.21; P = 0.37); no significant treatment-by-subgroup interaction was observed. Grade ≥3 adverse events occurred in 62.2% and 62.1% of patients, respectively. Grade ≥3 diarrhoea (15.6% versus 3.8%) and fatigue (7.3% versus 1.8%) were more frequent with mFOLFIRINOX, whereas grade ≥3 neutropenia was less frequent (18.0% versus 23.9%). Granulocyte colony-stimulating factor use was 37.8% versus 19.1%.</p><p><strong>Conclusion: </strong>Adjuvant mFOLFIRINOX triplet chemotherapy did not improve DFS compared with standard doublet mFOLFOX6 in patients with high-risk stage III colon cancer. These findings do not support empirical chemotherapy intensification and highlight the need for novel adjuvant strategies.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2026-10-25DOI: 10.1016/j.annonc.2026.10.108
Renaud Descourt, Alice Mogenet, Maelys Consigny, Marie Bernardi, Romain Corre, Olivier Bylicki, Jean-Bernard Auliac, Alain Vergnenègre, Charles Ricordel, Julian Pinsolle, Marie Wislez, Maud Pedrono, Rémi Veillon, Lionel Falchero, Florian Guisier, Pierre-Alexandre Hauss, Acya Bizieux-Thaminy, Stéphane Hominal, Anne Madroszyk, Hubert Curcio, Roland Schott, Eric Huchot, Benjamin Besse, Chrystèle Locher, Jacques Le Treut, Marie-Capucine Willemin, Géraldine François, Arnaud Uguen, Maurice Pérol, Christos Chouaïd, Laurent Greillier, Chantal Decroisette
{"title":"Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).","authors":"Renaud Descourt, Alice Mogenet, Maelys Consigny, Marie Bernardi, Romain Corre, Olivier Bylicki, Jean-Bernard Auliac, Alain Vergnenègre, Charles Ricordel, Julian Pinsolle, Marie Wislez, Maud Pedrono, Rémi Veillon, Lionel Falchero, Florian Guisier, Pierre-Alexandre Hauss, Acya Bizieux-Thaminy, Stéphane Hominal, Anne Madroszyk, Hubert Curcio, Roland Schott, Eric Huchot, Benjamin Besse, Chrystèle Locher, Jacques Le Treut, Marie-Capucine Willemin, Géraldine François, Arnaud Uguen, Maurice Pérol, Christos Chouaïd, Laurent Greillier, Chantal Decroisette","doi":"10.1016/j.annonc.2026.10.108","DOIUrl":"https://doi.org/10.1016/j.annonc.2026.10.108","url":null,"abstract":"<p><strong>Background: </strong>Pembrolizumab, alone or combined with platinum-based chemotherapy, is a standard first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable oncogenic alterations and with high programmed death-ligand 1 (PD-L1) expression. We conducted a head-to-head comparison of these two treatment strategies.</p><p><strong>Methods: </strong>In this multicenter, phase III trial (PERSEE, NCT04547504), adult patients with treatment-naïve stage IV or unresectable stage III NSCLC not amenable to definitive radiotherapy and PD-L1 expression ≥50% were randomly (1:1) assigned to receive pembrolizumab (200 mg every 3 weeks, for up to 35 cycles) or pembrolizumab in combination with four cycles of induction chemotherapy, stratified according to the presence of brain metastases and histologic subtype. Patients with non-squamous histology received cisplatin or carboplatin (AUC 5) plus pemetrexed, followed by pembrolizumab-pemetrexed maintenance; patients with squamous histology received carboplatin (AUC 6) plus paclitaxel, followed by pembrolizumab maintenance. The primary endpoint was progression-free survival (PFS), assessed by blinded central review according to RECIST v1.1. Key secondary endpoints included overall survival (OS), objective response rate, duration of response, and safety.</p><p><strong>Results: </strong>A total of 321 patients underwent randomization, with 160 assigned to pembrolizumab plus chemotherapy and 161 to pembrolizumab monotherapy. At a median follow-up of 38.7 months, median PFS was significantly longer with combination therapy than with monotherapy (16.1 months [95% CI, 11.0-34.1] vs. 6.9 months [95% CI, 5.5-9.3]; hazard ratio (HR), 0.56; 95% CI, 0.43-0.74; P<0.001). Median OS was 50.2 months versus 29.9 months, respectively (HR, 0.77; 95% CI, 0.56-1.05). Grade ≥3 treatment-related adverse events occurred in 54% and 19% of patients, respectively; grade ≥3 immune-related adverse events occurred in 13% of patients in each group.</p><p><strong>Conclusions: </strong>Among patients with treatment-naïve advanced NSCLC and high PD-L1 expression, the addition of platinum-based chemotherapy to pembrolizumab significantly prolonged PFS compared with pembrolizumab monotherapy.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2026-10-25DOI: 10.1016/j.annonc.2026.10.1281
Brian I Rini, Toni K Choueiri, Martin H Voss, Mauricio Burotto, Jan Oldenburg, Howard P Gurney, Thomas R Ferguson, Hans Hammers, Laurence Albiges, Yüksel Ürün, Roberto I Romero Diaz, Mustafa Özgüroğlu, Patricio Yañez Weber, Elena Verzoni, Camillo Porta, Alexandra Drakaki, Jun Guo, Nobuaki Matsubara, Aiying Chen, Joseph E Burgents, Karla G Rodriguez-Lopez, Thomas B Powles
{"title":"Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.","authors":"Brian I Rini, Toni K Choueiri, Martin H Voss, Mauricio Burotto, Jan Oldenburg, Howard P Gurney, Thomas R Ferguson, Hans Hammers, Laurence Albiges, Yüksel Ürün, Roberto I Romero Diaz, Mustafa Özgüroğlu, Patricio Yañez Weber, Elena Verzoni, Camillo Porta, Alexandra Drakaki, Jun Guo, Nobuaki Matsubara, Aiying Chen, Joseph E Burgents, Karla G Rodriguez-Lopez, Thomas B Powles","doi":"10.1016/j.annonc.2026.10.1281","DOIUrl":"https://doi.org/10.1016/j.annonc.2026.10.1281","url":null,"abstract":"<p><strong>Background: </strong>Pembrolizumab plus lenvatinib is a first-line standard of care for advanced clear-cell renal-cell carcinoma (ccRCC). The phase 3 LITESPARK-012 study (NCT04736706) evaluated efficacy and safety of adding belzutifan (HIF-2α inhibitor) or quavonlimab (anti-CTLA-4) to this regimen.</p><p><strong>Participants and methods: </strong>Adults with previously untreated advanced ccRCC were randomized 1:1:1 to 400 mg pembrolizumab IV Q6W plus 20 mg lenvatinib orally daily and 120 mg belzutifan orally daily (Arm A); coformulated quavonlimab/pembrolizumab 25 mg/400 mg IV Q6W (collectively called MK-1308A) plus lenvatinib (Arm B); or standard-of-care pembrolizumab plus lenvatinib (Control). Treatment continued until progression, unacceptable toxicity, or withdrawal from study; pembrolizumab or quavonlimab/pembrolizumab were administered for a maximum of ∼2 years. Progression-free survival (PFS) by blinded independent central review and overall survival (OS) were dual primary endpoints, tested in all randomized participants for Arm A versus Control, and in participants with IMDC intermediate/poor risk or all participants for Arm B versus Control. Safety was a secondary endpoint.</p><p><strong>Results: </strong>Overall, 560 participants were randomized to Arm A, 562 to Arm B, and 566 to Control. As of the data cutoff date (February 4, 2026), median follow-up was 43.6 months (range, 31.8-57.4). Among all participants, median PFS was 20.8 months in Arm A (HR vs Control: 1.08, 95%CI 0.93-1.26; P=0.8408), 20.7 months in Arm B (HR vs Control: 1.07, 95%CI 0.92-1.25; nominal P=0.8174), and 23.7 months in the Control arm; median OS was 52.0 months in Arm A (HR vs Control: 1.04, 95%CI 0.87-1.25; P=0.6622), not reached (NR) in Arm B (HR vs Control: 1.12, 95%CI 0.94-1.35; nominal P=0.8955), and NR in the Control arm. Among participants with intermediate/poor risk, median PFS was 20.5 months in Arm B and 23.5 months in the Control arm (HR 1.12, 95%CI 0.94-1.33; P=0.8954); median OS was 39.1 versus 46.2 months (HR 1.17, 95%CI 0.96-1.42; P=0.9419). Any-grade all-cause adverse events led to any-drug discontinuation in 51.6%, 51.4%, and 36.2% of participants in the A, B, and Control arms.</p><p><strong>Conclusions: </strong>Neither addition of the HIF-2α inhibitor belzutifan nor the CTLA-4 inhibitor quavonlimab to pembrolizumab plus lenvatinib improved outcomes in participants with previously untreated advanced RCC versus pembrolizumab and lenvatinib alone. Higher drug discontinuation rates due to adverse events occurred in the investigational arms. Efficacy and safety of standard-of-care pembrolizumab plus lenvatinib was consistent with prior reports.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2026-10-25DOI: 10.1016/j.annonc.2026.10.1280
Andrea Cercek, Jean-Baptiste Bachet, Gunnar Folprecht, Hideaki Bando, Jenny Seligmann, Naureen Starling, Maria Carmen Riesco-Martinez, Pilar Garcia Alfonso, Denis Smith, Lisa Salvatore, Encarna Gonzalez Flores, Emmanuel Mitry, Eric Chen, Jaume Capdevila Castillon, Federica Morano, Susana Roselló Keränen, Francine Aubin, Carlos López López, Sara Lonardi, Gary Buchschacher, Christoph Roderburg, Marco Gerlinger, Dominik Modest, Volker Heinemann, Thorsten Oliver Goetze, Takeshi Kato, Young Suk Park, Géraldine Perkins, Frédéric Lemay, Michael Vickers, Zsolt Szijgyarto, Neda Stjepanovic, Sina Haftchenary, Luis A Diaz, Jeanine M L Roodhart
{"title":"Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial.","authors":"Andrea Cercek, Jean-Baptiste Bachet, Gunnar Folprecht, Hideaki Bando, Jenny Seligmann, Naureen Starling, Maria Carmen Riesco-Martinez, Pilar Garcia Alfonso, Denis Smith, Lisa Salvatore, Encarna Gonzalez Flores, Emmanuel Mitry, Eric Chen, Jaume Capdevila Castillon, Federica Morano, Susana Roselló Keränen, Francine Aubin, Carlos López López, Sara Lonardi, Gary Buchschacher, Christoph Roderburg, Marco Gerlinger, Dominik Modest, Volker Heinemann, Thorsten Oliver Goetze, Takeshi Kato, Young Suk Park, Géraldine Perkins, Frédéric Lemay, Michael Vickers, Zsolt Szijgyarto, Neda Stjepanovic, Sina Haftchenary, Luis A Diaz, Jeanine M L Roodhart","doi":"10.1016/j.annonc.2026.10.1280","DOIUrl":"https://doi.org/10.1016/j.annonc.2026.10.1280","url":null,"abstract":"<p><strong>Background: </strong>Multimodal treatment with chemotherapy, radiation, and surgery for locally advanced rectal cancer (LARC) is a standard of care (SOC) associated with significant toxicity/morbidity. After TNT, clinical complete response (cCR) ranges between 21-41%, highlighting the need for novel approaches. dMMR/MSI-H tumors are exceptionally responsive to PD-1 blockade: in a pilot study, patients with dMMR/MSI-H LARC achieved durable responses after neoadjuvant dostarlimab. AZUR-1 is the first global registrational study evaluating dostarlimab monotherapy in adults with previously untreated stage II/III dMMR/MSI-H LARC.</p><p><strong>Methods: </strong>Dostarlimab 500 mg was administered intravenously Q3W for 9 cycles. Key endpoints include rate of sustained cCR for 12 months (cCR12) following end of treatment (EOT) with dostarlimab alone by investigator and independent central review (ICR), and composite rate of cCR12 (INV) + pathological CR (pCR).</p><p><strong>Results: </strong>At data cutoff (April 20, 2026), 154 patients were enrolled (median follow-up [range]: 26.3 [2-36] months). Of 144 patients with ≥12 months follow-up, 68% achieved cCR12 (INV). pCR was achieved in 12/15 patients (80%) who underwent surgery after dostarlimab alone: cCR12+pCR rate was 76%. cCR12 (ICR) was less mature than investigator, as first cCR (ICR) was identified at later timepoints. 98% who achieved cCR maintained cCR for ≥12 months. Overall, 93% of patients were on study with no evidence of disease progression after treatment (dostarlimab ± SOC); 71% achieved this outcome with dostarlimab alone. There were no reported recurrences for patients in cCR or pCR. Safety was acceptable; grade ≥3 immune-mediated AEs occurred in 4 (3%) patients. PROs showed meaningful improvements from baseline to EOT for several domains.</p><p><strong>Conclusions: </strong>In this AZUR-1 interim analysis, 68% of patients achieved cCR12 and 76% achieved cCR12+pCR with dostarlimab alone and had no disease recurrences. These durable responses indicate the potential to eliminate the need for current SOC and redefine the curative-intent treatment paradigm with dostarlimab in dMMR/MSI-H LARC.</p><p><strong>Trial registration number: </strong>NCT05723562.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2026-10-25DOI: 10.1016/j.annonc.2026.10.1286
Ken Herrmann
{"title":"From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology's New Pillar.","authors":"Ken Herrmann","doi":"10.1016/j.annonc.2026.10.1286","DOIUrl":"https://doi.org/10.1016/j.annonc.2026.10.1286","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2026-10-25DOI: 10.1016/j.annonc.2026.10.109
D Y C Heng, M Schmidinger, R McDermott, S H Park, M Burotto, C Ciccarese, E Verzoni, C Suárez, M Eto, H J Cutuli, C Porta, R Manneh Kopp, S Rottey, G de Velasco, B P Valderrama, A A Azad, U De Giorgi, M Pavic, P Tomczak, R Figlin, H M Westgeest, A Guida, A Necchi, F A Schutz, B B M Suelmann, J B A G Haanen, J Lin, R F Perini, D Vickery, R J Motzer
{"title":"Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy.","authors":"D Y C Heng, M Schmidinger, R McDermott, S H Park, M Burotto, C Ciccarese, E Verzoni, C Suárez, M Eto, H J Cutuli, C Porta, R Manneh Kopp, S Rottey, G de Velasco, B P Valderrama, A A Azad, U De Giorgi, M Pavic, P Tomczak, R Figlin, H M Westgeest, A Guida, A Necchi, F A Schutz, B B M Suelmann, J B A G Haanen, J Lin, R F Perini, D Vickery, R J Motzer","doi":"10.1016/j.annonc.2026.10.109","DOIUrl":"10.1016/j.annonc.2026.10.109","url":null,"abstract":"<p><strong>Background: </strong>The phase III, randomized, open-label LITESPARK-011 trial (NCT04586231) investigated belzutifan plus lenvatinib versus cabozantinib in participants with advanced clear-cell renal cell carcinoma (ccRCC) following anti-programmed death-ligand 1 or anti-programmed death-1 [anti-PD-(L)1] therapy. At earlier analyses, belzutifan plus lenvatinib significantly improved progression-free survival (PFS) and objective response rate (ORR) versus cabozantinib. Overall survival (OS) was tested but did not reach significance. We present the final analysis of LITESPARK-011.</p><p><strong>Participants and methods: </strong>Adult participants with advanced ccRCC that progressed on or after anti-PD-(L)1 therapy were randomly assigned (1 : 1) to 120 mg belzutifan plus 20 mg lenvatinib or 60 mg cabozantinib orally once daily until disease progression or unacceptable adverse events. Dual primary endpoints were PFS by blinded independent central review (BICR) and OS. ORR by BICR was a key secondary endpoint; safety and duration of response (DOR) by BICR were secondary endpoints.</p><p><strong>Results: </strong>At final analysis, median time from randomization to data cut-off date (2 February 2026) was 38.8 months (range, 29.1-59.0). A total of 371 participants were assigned to belzutifan plus lenvatinib and 376 to cabozantinib. Belzutifan plus lenvatinib continued to demonstrate benefit versus cabozantinib in PFS [hazard ratio (HR) 0.74, 95% confidence interval (CI) 0.62-0.88], ORR (53.1% versus 40.2%), and DOR (22.0 versus 11.9 months). Mature OS results did not reach statistical significance at final analysis [median 33.7 versus 28.6 months; HR 0.85, 95% CI 0.70-1.03; one-sided P = 0.04689 (prespecified boundary 0.0223)]. Grade ≥3 treatment-emergent adverse events occurred in 85.4% of the belzutifan plus lenvatinib group versus 83.0% of the cabozantinib group.</p><p><strong>Conclusions: </strong>Belzutifan plus lenvatinib continued to demonstrate PFS, ORR, and DOR benefit versus cabozantinib with additional follow-up; OS favored the combination but did not reach statistical significance at final analysis. Safety profile of belzutifan plus lenvatinib remained consistent with each drug as monotherapy. These findings continue to support belzutifan plus lenvatinib as a treatment option in advanced ccRCC following anti-PD-(L)1 therapy.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2026-10-24DOI: 10.1016/j.annonc.2026.10.1282
A Giordano, B Xu, T Yoshinami, C-S Huang, Y H Park, G L Lerzo, H Li, A Shai, G Garnica Jaliffe, M Itoh, A Williams, S Goel, S-A Im, P Cobb, M Golmakani, F Liu, R A Moss, A Vana, M Ignatiadis, H S Rugo
{"title":"Atirmociclib and fulvestrant for patients with HR-positive/HER2-negative advanced or metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.","authors":"A Giordano, B Xu, T Yoshinami, C-S Huang, Y H Park, G L Lerzo, H Li, A Shai, G Garnica Jaliffe, M Itoh, A Williams, S Goel, S-A Im, P Cobb, M Golmakani, F Liu, R A Moss, A Vana, M Ignatiadis, H S Rugo","doi":"10.1016/j.annonc.2026.10.1282","DOIUrl":"10.1016/j.annonc.2026.10.1282","url":null,"abstract":"<p><strong>Background: </strong>Atirmociclib is a potential first-in-class, highly selective cyclin-dependent kinase (CDK) 4 inhibitor that demonstrates significantly greater selectivity for CDK4 over CDK6. In a phase I-IIa study, atirmociclib plus endocrine therapy was well tolerated and showed encouraging antitumor activity in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (mBC). We present results from a randomized study of atirmociclib plus fulvestrant versus investigator's choice of therapy (ICT) in patients with HR-positive/HER2-negative mBC whose disease progressed on prior adjuvant or first-line CDK4/6 inhibitor treatment.</p><p><strong>Patients and methods: </strong>FourLight-1 (NCT06105632) is an open-label phase II study. Patients were randomly assigned 1:1 to atirmociclib (300 mg orally, twice daily, continuously) plus fulvestrant or ICT (fulvestrant alone or everolimus plus exemestane). The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival, objective response rate (ORR), duration of response (DOR), clinical benefit rate (CBR), and safety.</p><p><strong>Results: </strong>At the data cut-off (12 January 2026), 263 patients were enrolled (atirmociclib, n = 126; ICT, n = 137; median age: 57 years). PFS was significantly improved with atirmociclib compared with ICT (stratified hazard ratio 0.60, 95% CI 0.440-0.825, one-sided P = 0.0007; median 9.4 compared with 6.6 months). A consistent PFS benefit was observed across most subgroups. Patients with baseline measurable disease in the atirmociclib arm had a higher ORR than those in the ICT arm [21 (19.3%) compared with 13 (11.3%); nominal two-sided P = 0.0901], and median DOR was numerically longer (14.8 compared with 9.3 months, respectively); CBR was 61.9% compared with 46.0%, respectively. The most common any-grade treatment-emergent adverse events (TEAEs) in the atirmociclib arm were neutropenia (47.2%), leukopenia (33.6%), and diarrhea (28.0%); 6.4% of patients discontinued atirmociclib due to TEAEs.</p><p><strong>Conclusions: </strong>Atirmociclib plus fulvestrant showed significant and clinically meaningful PFS improvement in patients who progressed on prior CDK4/6 inhibitor treatment, with a manageable safety and tolerability profile.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2026-10-24DOI: 10.1016/j.annonc.2026.10.1285
H S Rugo, M Kok, A Goncalves, D Loirat, G Bianchini, P A Fasching, D W Cescon, R Romero Díaz, F Zagouri, E Korbenfeld, F Dalenc, Y Jerez Gilarranz, J Hashimoto, Y H Park, S-A Im, X Hu, K M Hirshfield, L Jia, K Tryfonidis, P Schmid
{"title":"Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.","authors":"H S Rugo, M Kok, A Goncalves, D Loirat, G Bianchini, P A Fasching, D W Cescon, R Romero Díaz, F Zagouri, E Korbenfeld, F Dalenc, Y Jerez Gilarranz, J Hashimoto, Y H Park, S-A Im, X Hu, K M Hirshfield, L Jia, K Tryfonidis, P Schmid","doi":"10.1016/j.annonc.2026.10.1285","DOIUrl":"https://doi.org/10.1016/j.annonc.2026.10.1285","url":null,"abstract":"<p><strong>Background: </strong>We evaluated pembrolizumab plus chemotherapy versus chemotherapy alone in participants with PD-L1‒positive, hormone receptor-positive (HR+)/HER2- advanced breast cancer after progression on prior endocrine-based therapy (ET).</p><p><strong>Patients and methods: </strong>Participants with locally recurrent inoperable or metastatic HR+/HER2- breast cancer with PD-L1 combined positive score (CPS) ≥1 who had prior ET and were candidates for first-line chemotherapy were randomized to pembrolizumab 200 mg or placebo Q3W plus chemotherapy. The primary and key secondary endpoints were progression-free survival (PFS) per RECIST v1.1 by blinded independent central review and overall survival (OS), respectively, in participants with PD-L1 CPS ≥1. PFS and OS in participants with PD-L1 CPS ≥10 and safety were secondary endpoints. Following protocol amendment, the sample size was reduced due to low PD-L1 prevalence.</p><p><strong>Results: </strong>342 participants were randomized. At interim analysis (median follow-up, 29.1 months), the hazard ratio (HR) for PFS was 0.74 (95% CI, 0.58‒0.95; P=0.0089 [significance criterion met]) favoring pembrolizumab plus chemotherapy versus placebo plus chemotherapy (median [95% CI] PFS, 6.7 [6.2‒8.3] versus 6.0 [4.2‒8.1] months). HR for PFS in participants with PD-L1 CPS ≥10 numerically favored pembrolizumab plus chemotherapy (0.59; 95% CI, 0.35‒0.98). At final analysis (median follow-up, 34.9 months), HR for OS was 1.04 (95% CI, 0.81‒1.33; P=0.6185) for pembrolizumab plus chemotherapy versus placebo plus chemotherapy (median [95% CI] OS, 21.0 [18.9‒22.9] versus 22.2 [17.6‒26.3] months). Grade ≥3 treatment-related AEs occurred in 38% of participants in the pembrolizumab plus chemotherapy arm and 33% in the placebo plus chemotherapy arm; 11% and 5% discontinued treatment due to treatment-related AEs, respectively.</p><p><strong>Conclusion: </strong>In participants with PD-L1‒positive (CPS ≥1) HR+/HER2- advanced breast cancer, pembrolizumab plus chemotherapy demonstrated statistically significant improvement in PFS, with no new safety signals observed. A numerical effect favoring pembrolizumab plus chemotherapy for PFS was observed in participants with PD-L1 CPS ≥10. No significant OS improvement was observed.</p><p><strong>Clinical trial registration: </strong>KEYNOTE-B49; ClinicalTrials.gov, NCT04895358.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2026-10-24DOI: 10.1016/j.annonc.2026.09.009
S Lonardi, H-J Lenz, E Elez, L H Jensen, E Van Cutsem, Y Touchefeu, R Rocio Garcia-Carbonero, D Tougeron, G A Mendez, M Schenker, C de la Fouchardière, M L Limón Mirón, T Yoshino, J Li, J L Manzano Mozo, L Dahan, G Tortora, M Chalabi, E Goekkurt, M I Braghiroli, R Joshi, T Cil, F Aubin, V Raparthi, A Wang, S Rodriguez, E Cela, L Li, R Tam, L Jin, T André
{"title":"Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW.","authors":"S Lonardi, H-J Lenz, E Elez, L H Jensen, E Van Cutsem, Y Touchefeu, R Rocio Garcia-Carbonero, D Tougeron, G A Mendez, M Schenker, C de la Fouchardière, M L Limón Mirón, T Yoshino, J Li, J L Manzano Mozo, L Dahan, G Tortora, M Chalabi, E Goekkurt, M I Braghiroli, R Joshi, T Cil, F Aubin, V Raparthi, A Wang, S Rodriguez, E Cela, L Li, R Tam, L Jin, T André","doi":"10.1016/j.annonc.2026.09.009","DOIUrl":"10.1016/j.annonc.2026.09.009","url":null,"abstract":"<p><strong>Background: </strong>The phase III CheckMate 8HW trial met its dual primary endpoints of superior progression-free survival (PFS) with nivolumab plus ipilimumab (NIVO + IPI) versus chemotherapy [first-line (1L)] and versus NIVO (all lines) in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC). We report prespecified final overall survival (OS) analyses and updated efficacy outcomes.</p><p><strong>Patients and methods: </strong>Immunotherapy-naïve adults with mCRC across different lines and MSI-H/dMMR by local testing were randomly assigned 2 : 2 : 1 to NIVO (240 mg) plus IPI (1 mg/kg) once every 3 weeks for four doses and then NIVO 480 mg once every 4 weeks; NIVO (240 mg) once every 2 weeks (six doses) and then 480 mg once every 4 weeks; or chemotherapy ± targeted therapies. Secondary endpoints include PFS in NIVO + IPI versus NIVO (1L) and OS and objective response rate in the centrally confirmed MSI-H/dMMR population.</p><p><strong>Results: </strong>In total, 839 patients across all lines were randomly assigned; efficacy analyses were conducted in those with centrally confirmed MSI-H/dMMR. Median follow-up across all lines and treatment groups was 68.0 months (range 37.6-81.4 months). NIVO + IPI demonstrated significant OS benefit compared with NIVO across all lines [hazard ratio (HR) 0.61, 95% confidence interval (CI) 0.46-0.82, P = 0.0009] and with chemotherapy in 1L (HR 0.37, 95% CI 0.24-0.57, P < 0.0001). Clinically meaningful OS benefit was noted with 1L NIVO + IPI versus NIVO (HR 0.66, 95% CI 0.44-0.99, P = 0.0432), not meeting the prespecified threshold for significance (P < 0.006). PFS continued to favor NIVO + IPI across all three comparisons: NIVO (all lines; HR 0.60), chemotherapy (1L; HR 0.21), and NIVO (1L; HR 0.68). Grade 3/4 treatment-related adverse events occurred in 78 (22%) versus 50 (14%) patients treated with NIVO + IPI versus NIVO across all lines, with no new safety concerns or additional treatment-related deaths from the previous follow-up.</p><p><strong>Conclusions: </strong>NIVO + IPI showed significant OS benefit compared with NIVO across all lines and with chemotherapy in 1L, while providing a clinical OS benefit versus NIVO in 1L, reinforcing its standard-of-care status in MSI-H/dMMR mCRC.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}